Predictors of 30-day readmissions after catheter ablation for atrial fibrillation in the USA
- 181 Downloads
Catheter ablation is considered as the mainstay treatment for patients with symptomatic atrial fibrillation (AF). We aimed to determine the predictors of 30-day readmission after catheter ablation for AF.
The study cohort consisted of patients who underwent AF catheter ablation (International Classification of Diseases, Ninth Revision 427.31 and procedure code 37.34) in 2014, identified from the National Readmission Database.
Our final cohort consisted of 5322 unweighted cases, of which 4736 (89%) constituted the no-readmission group and 586 patients (11%) the readmission group. Female gender (OR 1.62, 95% CI 1.35–1.95), CAD (OR 1.36, 95% CI 1.08–1.71), peripheral vascular disease (OR 1.45, 95% CI 1.07–1.98), acute renal failure (OR 1.46, 95% CI 1.09–1.97), fluid and electrolyte disorders (OR 1.32, 95% CI 1.03–1.67), chronic pulmonary disease (OR 1.25, 95% CI 1.01–1.53), ablation on the day of admission (OR 0.74, 95% CI 0.61–0.91), and fourth quartile of hospital AF catheter ablation volume (OR 0.60, 95% CI 0.45–0.80) were independent predictors of 30-day readmission. Arrhythmias and heart failure were the most common cardiac etiologies for readmission. The most common ablation-related complications were hemorrhage (11%) and vascular (7%) complications.
Several patient- and hospital-related factors were identified as predictors of 30-day readmission, the knowledge of which can potentially improve healthcare delivery.
KeywordsCatheter ablation Atrial fibrillation Readmission National Readmission Database
National Inpatient Sample
National Readmission Database
International Classification of Diseases, Ninth Revision, Clinical Modification
Length of stay
Coronary artery disease
Peripheral vascular disease
Acute renal failure
Sinus node dysfunction
Transient ischemic attack
The cost of software and database was funded by Dorothy Rider Pool Trust Fund (Grant: 1573-007), Lehigh Valley Health Network.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Prevention DfHDaS (2015) Atrial Fibrillation Fact Sheet. Accessed on Jul 17, 2017. Available from https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Centers for Disease Control and Prevention.
- 3.Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57(2):223–42. https://doi.org/10.1016/j.jacc.2010.10.001.CrossRefPubMedGoogle Scholar
- 4.Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528–606. https://doi.org/10.1093/europace/eus027.CrossRefPubMedGoogle Scholar
- 5.Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111(9):1100–5. https://doi.org/10.1161/01.CIR.0000157153.30978.67.CrossRefPubMedGoogle Scholar
- 8.Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation. 2013;128(19):2104–12. https://doi.org/10.1161/CIRCULATIONAHA.113.003862.CrossRefPubMedGoogle Scholar
- 14.Curtis JP, Schreiner G, Wang Y, Chen J, Spertus JA, Rumsfeld JS, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of Medicare patients. J Am Coll Cardiol. 2009;54(10):903–7. https://doi.org/10.1016/j.jacc.2009.04.076.CrossRefPubMedGoogle Scholar
- 19.Mulder AA, Wijffels MC, Wever EF, Boersma LV. Early recurrence of atrial fibrillation as a predictor for 1-year efficacy after successful phased RF pulmonary vein isolation: evaluation of complaints and multiple Holter recordings. Int J Cardiol. 2013;165(1):56–60. https://doi.org/10.1016/j.ijcard.2011.07.079.CrossRefPubMedGoogle Scholar